Want to join the conversation?
For full-year 2016, $GILD expects non-GAAP net product sales to be in the range of $29.5-30.5Bil, R&D expenses to be between $3.6-3.8Bil, SG&A to be between $3.1-3.3Bil and effective tax rate to be between 18-20%. Diluted EPS, including certain items, is expected to be in the range of $1.47-1.53 for full-year 2016.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.
Well this is big! I don’t know if it’s someone’s monopoly or genuine excitement, but either way, $CSX is up 23% after market closed. I heard some activist investor is going to blow big money into CSX Corp. Anyone mind explaining?